The Criteria for the clinical use of immunoglobulin in Australia (the Criteria) undergoes periodic review to reflect the latest scientific evidence and expert advice from our National Immunoglobulin Governance Advisory Committee and its Specialist Working Groups.
This page summarises the changes to the Criteria which were implemented prior to 2020. Changes are applied immediately to new authorisations and to existing authorisations at the next continuing treatment request, unless otherwise stated. For more information about any of these changes, please contact the Ig Governance team at IgGovernance@blood.gov.au.
October 2019
Acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation (HSCT) – Version 3.2
- An additional one-off dose now available during the course of the authorisation.
- Separate doses now available for IVIg and SCIg.
- Other minor typographical changes.
Chronic inflammatory demyelinating polyneuropathy (CIDP), (including IgG and IgA paraproteinaemic demyelinating neuropathies) – Version 3.2
- An additional one-off dose now available during the course of the authorisation.
- Separate doses now available for IVIg and SCIg.
Primary immunodeficiency diseases (PID) with antibody deficiency – Version 3.2
- An additional one-off dose now available during the course of the authorisation.
- Separate doses now available for IVIg and SCIg.
- Other minor typographical changes.
Secondary hypogammaglobulinaemia unrelated to haematological malignancy or haemopoietic stem cell transplant (HSCT) – Version 3.2
- An additional one-off dose now available during the course of the authorisation.
- Separate doses now available for IVIg and SCIg.
- Other minor typographical changes.
Specific antibody deficiency – Version 3.1
- Separate doses now available for IVIg and SCIg.
August 2019
Chronic inflammatory demyelinating polyneuropathy (CIDP), (including IgG and IgA paraproteinaemic demyelinating neuropathies) – Version 3.1
- SCIg can now be considered as an alternative to IVIg, following stabilisation with IVIg.
- Other minor typographical changes.
May 2019
Opsoclonus-myoclonus ataxia (OMA) – Version 3.1
- Minor typographical changes.
April 2019
Anti-neutrophil cytoplasmic antibody (ANCA) [Proteinase 3 (PR3) or myeloperoxidase (MPO)]-positive systemic necrotising vasculitis – Version 3.1
- Minor typographical changes.
Last updated: 03 Feb 2026